Advertisement
Screener

ONCOLYTICS BIOTECH INC. (ONCY) Revenue From Contracts With Customers

2.0 / 5 stars · 16/40 Roast Me

ONCOLYTICS BIOTECH INC. Revenue From Contracts With Customers

ONCOLYTICS BIOTECH INC. (ONCY) reported Revenue From Contracts With Customers of CAD 0 for the 12-month period ending 2021-12-31, per its 20-F filed 2022-03-03.

Discontinued › Income Statement

ifrs-full:RevenueFromContractsWithCustomers · last filed 2022-03-03

CAD

Period endRevenue From Contracts With Customers 12 month
2021-12-310.00 CAD
20-F · filed 2022-03-03
2020-12-310.00 CAD
20-F · filed 2022-03-03
2019-12-310.00 CAD
20-F · filed 2021-03-05
2018-12-31547.71K CAD
20-F · filed 2020-03-06
2017-12-316.18M CAD
20-F · filed 2019-03-15

USD

Period endRevenue From Contracts With Customers 12 month
2017-12-31$6.18M
20-F · filed 2018-03-19
2016-12-31$0.00
20-F · filed 2018-03-19

Similar stocks

Stock NameCountryMarket CapPE Ratio
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)United States$0.086B
Lexaria Bioscience Corp. (LEXX)$0.084B-1.92
Telomir Pharmaceuticals, Inc. (TELO)United States$0.084B
Rallybio Corp (RLYB)United States$0.089B
Acrivon Therapeutics, Inc. (ACRV)United States$0.091B-1.03
Gain Therapeutics, Inc. (GANX)United States$0.080B-4.40
Lifevantage Corp (LFVN)United States$0.078B15.40
Adicet Bio, Inc. (ACET)United States$0.078B-0.81
Valion Bio, Inc. (VBIO)United States$0.077B
MAIA Biotechnology, Inc. (MAIA)United States$0.077B-2.30